As the world is still battling with the Covid-19 Virus, the trials of the vaccine are also catching pace. Lately, Oxford’s Covid-19 Vaccine that was paused in between has resumed and therefore it has shown some effective results on the elderly age group.
Oxford’s covid-19 vaccine is undergoing trials in India. Pune-based Serum Institute is making potential vaccines from AstraZeneca, Novavax, and Codagenix Inc, as well as developing its own.
The elderly people are seen at the highest risk from the coronavirus.AstraZeneca’s vaccine has produced a strong immune response in elderly aged people, as per the reports. Citing two unidentified people familiar with the finding. The vaccine, which AstraZeneca is producing in collaboration with the University of Oxford, produced protective antibodies and T-cells in older age groups.
Findings on immunogenicity blood tests carried on a subset of older participants echo data released in July that showed the vaccine generated “robust immune responses” in healthy adults aged 18-55 years, the report said.
The Oxford covid vaccine is considered a frontrunner in the race to Covid-19 vaccine and the outcome of the trials is being closely watched around the world.
The British-Swedish drugmaker has signed several supplies and manufacturing deals with companies and governments around the world as it gets closer to reporting early results of a late-stage clinical trial.
Named AZD1222 (ChAdOx1 nCoV-19) vaccine the Oxford covid vaccine is a recombinant viral vector vaccine. It uses a weakened version of a chimpanzee common cold virus that encodes instructions for making proteins from the novel coronavirus to generate an immune response and prevent infection.
ALSO READ: China’s Nasal Spray COVID-19 Vaccine To Start Phase 1 Trials In November
Follow Flickonclick on Google News